bluebird bio Inc at Morgan Stanley Global Healthcare Conference Transcript
Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have the team with us from bluebird this morning. Just quickly before we get started, I need to read a disclosure statement.
Please note that all important disclosures, including personal holdings disclosures are available on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So really pleased to have Andrew and Tom with me here. Maybe we should just start off, you had some management changes recently. Maybe we should just address what's going on there, and then we can jump into some of the products.
Yes. We announced yesterday that Jason Coles leaving, he's actually in the audience here. So he's not -- he hasn't gone far yet. So Jason actually stepped in as CFO at a really tough time for the company in March and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |